DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Adjunctive Quetiapine in the Treatment of Refractory Social Anxiety Disorder in Adults

Information source: Cambridge Health Alliance
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Social Anxiety Disorder

Intervention: Quetiapine (Drug)

Phase: Phase 4

Status: Active, not recruiting

Sponsored by: Cambridge Health Alliance

Official(s) and/or principal investigator(s):
Gustavo D Kinrys, MD, Principal Investigator, Affiliation: Cambridge Health Alliance; Harvard Medical School


This is a 16-week research study in which participants suffering from Social Anxiety Disorder (SAD) will receive Sertraline (a medication FDA approved for the treatment of SAD) for the first 8 weeks. If a participant remains symptomatic, he/she will enter the second phase of the study in which he/she continues taking Sertraline but also randomly receives either Seroquel or placebo in conjunction with Sertraline for additional 8 weeks. The purpose of this study is to determine the efficacy of adjunctive Seroquel in treating SAD.

Clinical Details

Official title: A Double-Blind, Placebo-Controlled, Flexible-Dosage Study to Evaluate the Efficacy and Safety of Adjunctive Quetiapine in the Treatment of Refractory Social Anxiety Disorder in Adults

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Primary outcome: Liebowitz Social Anxiety Scale (LSAS)

Secondary outcome: Clinical Global Impression of Improvement (CGI-I) scores

Detailed description: This will be a single-site study aimed at evaluating the safety, tolerability, and efficacy of quetiapine as compared to placebo in the treatment of generalized anxiety disorder. This will be an 8-week open-label sertraline trial followed by a randomized double-blind placebo-controlled, parallel-group prospective study. Participants will first receive

sertraline (25-200 mg/day) for 8 weeks. Patients who remain symptomatic - are considered

refractory - and meet inclusion criteria will be randomized and enter the double-blind

phase. They will receive either adjunctive quetiapine (25-400 mg/day) or placebo for 8 weeks. The primary outcome measures are change in the Liebowitz Social Anxiety Scale(LSAS) and Clinical Global Impression of Improvement (CGI-I) scores. The proposed sample size is 80 subjects. Patients will be discontinued from the study if needed due to ineffectiveness or excessive side effects. Measurements of changes in efficacy and side effects will be carried out every weekly visit. Enrollment will occur over 12 months.


Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.


Inclusion Criteria:

- Male and female outpatients, age 18-65.

- Diagnosis of Social Anxiety Disorder (SAD), generalized subtype, by DSM-IV criteria.

- Liebowitz Social Anxiety Scale (LSAS) rating greater than or equal to 50 for both


- Hamilton Depression Scale (HAM-D-17) score less than or equal to 16.

Exclusion Criteria:

- Pregnant or lactating women or others not using acceptable means of birth control

(e. g., IUD, oral contraceptives, barrier devices, condoms and foam, implanted progesterone rods stabilized for at least 3 months).

- Patients with current or history of bipolar disorder, schizophrenia, or other

psychotic conditions.

- Patients with a history of alcohol or substance abuse or dependence within the last

six months or a positive toxicology screen consistent with abuse at baseline.

- Patients with significant unstable medical illness, including any medical pathology

considered not well-controlled with conventional treatment, i. e., that may require during the study period medication adjustment, ongoing tests or procedures, intensive treatment or hospitalization. In addition, baseline laboratory tests will be conducted and required to be within normal limits or have no clinical significance for patient entry in the study.

- Severe personality disorders likely to interfere with study participation or who, in

the investigator's judgment, pose a current, serious suicidal or homicidal risk.

- Ongoing psychotherapy directed toward the treatment of social anxiety disorder.

- History of hypersensitivity to sertraline and quetiapine.

Locations and Contacts

Cambridge Health Alliance, Cambridge, Massachusetts 02139, United States
Additional Information

Starting date: March 2006
Last updated: October 18, 2010

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017